Cluster Headache Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Lundbeck Seattle Biopharmaceuticals, Clexio Biosciences
29 avr. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, April 29, 2024 (GLOBE NEWSWIRE) -- Cluster Headache Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Lundbeck Seattle...
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
13 mars 2024 16h05 HE
|
electroCore, Inc.
Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY,...
electroCore to Participate in Upcoming Investor Conferences
12 mars 2024 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Strategy...
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024
05 mars 2024 16h05 HE
|
electroCore, Inc.
ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
15 nov. 2023 08h15 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical...
electroCore Announces Third Quarter 2023 Financial Results
08 nov. 2023 16h01 HE
|
electroCore, Inc.
Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5...
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
11 oct. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
electroCore to Announce Third Quarter Financial Results on Wednesday, November 8
09 oct. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
27 sept. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of two peer...
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
26 sept. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...